Patents Assigned to Agenus Inc.
-
Patent number: 11897956Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.Type: GrantFiled: June 3, 2021Date of Patent: February 13, 2024Assignees: Merck Sharp & Dohme LLC, Agenus Inc.Inventors: Milan Blanusa, Barbara Joyce-Shaikh, Andrea Claudia Schuster, Kornelia Schultze, Luis A. Zuniga
-
Patent number: 11897962Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: August 21, 2020Date of Patent: February 13, 2024Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Patent number: 11897957Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.Type: GrantFiled: June 3, 2021Date of Patent: February 13, 2024Assignees: Merck Sharp & Dohme LLC, Agenus Inc.Inventors: Milan Blanusa, Barbara Joyce-Shaikh, Andrea Claudia Schuster, Kornelia Schultze, Luis A. Zuniga
-
Patent number: 11839653Abstract: Antibodies that specifically bind to TIM 3 and antagonize TIM-3 function pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: March 2, 2020Date of Patent: December 12, 2023Assignee: AGENUS INC.Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
-
Patent number: 11718669Abstract: The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.Type: GrantFiled: August 10, 2022Date of Patent: August 8, 2023Assignee: AGENUS INC.Inventors: Dhan Sidhartha Chand, Zahra Jawad, Olga Ignatovich, Nicola Anne Ramsay, Spencer Campbell, Beth Wensley, Emmanuel Cyrille Pascal Briend, K. Mark Bushell, Benjamin Maxime Morin, Veronica Franciszka Ilkow
-
Patent number: 11692042Abstract: The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGF?-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: March 8, 2019Date of Patent: July 4, 2023Assignee: AGENUS INC.Inventors: Nicholas Stuart Wilson, Jeremy Dale Waight, Shawn Michael Jennings, Olga Ignatovich, Emmanuel Cyrille Pascal Briend, Benjamin Maxime Morin, Oliver Schon, Spencer Campbell
-
Patent number: 11680098Abstract: The instant disclosure provides antibodies that specifically bind to CD96 (e.g., human CD96) and antagonize CD96 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: August 31, 2020Date of Patent: June 20, 2023Assignee: AGENUS INC.Inventors: Dhan Sidhartha Chand, Randi Barbara Gombos, Olga Ignatovich, Nicola Anne Ramsay, K. Mark Bushell, Emmanuel Cyrille Pascal Briend
-
Patent number: 11638755Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: December 14, 2020Date of Patent: May 2, 2023Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer CenterInventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
-
Patent number: 11472883Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: GrantFiled: March 3, 2020Date of Patent: October 18, 2022Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
-
Patent number: 11447557Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.Type: GrantFiled: December 2, 2016Date of Patent: September 20, 2022Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Nicholas S. Wilson, Jeremy D. Waight, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Ekaterina V. Breous-Nystrom, Volker Seibert, Takemasa Tsuji, Olivier Léger, Dennis J. Underwood, Marc Van Dijk
-
Patent number: 11414458Abstract: The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer.Type: GrantFiled: March 2, 2020Date of Patent: August 16, 2022Assignees: Agenus Inc., The Board of Regents of the University of OklahomaInventors: Donald F. Hunt, Andrew Norris, Ann Michelle English, Jeffrey Shabanowitz, William H. Hilderbrand, Oriana E. Hawkins
-
Patent number: 11401335Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: January 15, 2020Date of Patent: August 2, 2022Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Ana M. Gonzalez, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Patent number: 11359028Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies. The antibodies disclosed herein modulate OX40 and/or GITR activity e.g., enhance, activate, induce, reduce, deactivate, or inhibit OX40 and/or GITR activity. The present disclosure also provides methods for treating disorders, such as cancer, autoimmune diseases or disorders, or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and/or human GITR and modulates OX40 and/or GITR activity.Type: GrantFiled: May 9, 2019Date of Patent: June 14, 2022Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Nicholas S. Wilson, Jeremy D. Waight, Dennis J. Underwood, Ekaterina V. Breous-Nystrom, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Marc Van Dijk
-
Patent number: 11345755Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: April 24, 2020Date of Patent: May 31, 2022Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer CenterInventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky, Nicholas Stuart Wilson
-
Patent number: 11332536Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: GrantFiled: February 7, 2020Date of Patent: May 17, 2022Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Nicholas S. Wilson
-
Publication number: 20220106581Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: July 19, 2021Publication date: April 7, 2022Applicants: AGENUS INC., AGENUS INC.Inventors: Yanping XIAO, Nicholas Stuart WILSON, Benjamin Maxime MORIN, Mark Arthur FINDEIS, Cornelia Anne MUNDT, Marc van DIJK, Dhan Sidhartha CHAND, David Adam SAVITSKY, Dennis John UNDERWOOD, Olga IGNATOVICH
-
Patent number: 11267889Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: April 24, 2020Date of Patent: March 8, 2022Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer CenterInventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson
-
Patent number: 11242385Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: April 12, 2018Date of Patent: February 8, 2022Assignee: AGENUS INC.Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
-
Publication number: 20220033496Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.Type: ApplicationFiled: June 3, 2021Publication date: February 3, 2022Applicants: Merck Sharp & Dohme Corp., Agenus Inc.Inventors: Milan BLANUSA, Barbara JOYCE-SHAIKH, Andrea Claudia SCHUSTER, Kornelia SCHULTZE, Luis A. ZUNIGA
-
Publication number: 20220002403Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.Type: ApplicationFiled: June 3, 2021Publication date: January 6, 2022Applicants: Merck Sharp & Dohme Corp., Agenus Inc.Inventors: Milan Blanusa, Barbara Joyce-Shaikh, Andrea Claudia Schuster, Kornelia Schultze, Luis A. Zuniga